Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-Seq of transgenic plasma cells from the described subgroup-specific MM mouse models

ABSTRACT: RNA-Seq of transgenic plasma cells from the described subgroup-specific MM mouse models

PROVIDER: PRJNA759563 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

RNA-Seq of transgenic plasma cells from the described subgroup-specific MM mouse models

Project description:RNA expression profiling of control, single mutant (Ccnd1, MMSET or Ikk2ca) and double mutant (Ccnd1/Ikk2ca or MMSET/Ikk2ca) bone marrow plasma cells

2022-08-30 | GSE183177 | GEO

Chromatin accessibility and gene expression maps of Plasma Cells and Myeloma Plasma Cells [ATAC-seq]

Project description:We report the application of paired Assay for Transposase-Accessible Chromatin (ATAC-seq) and RNA-seq data to profile the regulatory landscape and expression of 5 primary Plasma Cell (PC), 28 Multiple Myeloma (MM) PC as well as 5 cell lines samples. Findings discriminated MM and MM subgroup-specific changes such as the exclusive overexpression of CCND1 and CCND2 oncogenes. DNA accessibility changes were correlated to gene expression in a topologically constrained manner to elucidate novel enhancer - promoter interactions, genes and pathways critical for myeloma biology and developmentally activated or de novo formed enhancers. Additionally, the MM subgroup-specific TF network dependencies were studied to help identify prognostic markers. Finally, we discover and functionally validate the critical enhancer that regulates ectopic expression of CCND2 in MM.

2021-06-29 | GSE153379 | GEO

Chromatin accessibility and gene expression maps of Plasma Cells and Myeloma Plasma Cells [RNA-seq]

2021-06-29 | GSE153380 | GEO

Transcriptomic profiling of normal plasma cells and MM models using bulk RNA-Seq

Project description:NRAS Q61 mutations are prevalent in advanced/relapsed multiple myeloma (MM) and correlate with poor patient outcomes. Thus, we generated a novel MM model by conditionally activating expression of endogenous NrasQ61R and a MYC transgene in germinal center B cells (VQ mice). VQ mice developed a highly malignant MM characterized by high proliferation index, hyperactivation of ERK and AKT signaling, impaired hematopoiesis, widespread extramedullary disease, bone lesions, kidney abnormalities, preserved PD1 and TIGIT immune checkpoint pathways, and expression of human high-risk MM gene signatures. VQ MM mice recapitulate most of the biological and clinical features of human advanced/high-risk MM. These MM phenotypes are serially transplantable in syngeneic recipients. Two MM cell lines were also derived to facilitate future genetic manipulations. Combination therapies based on MEK inhibition significantly prolonged the survival of VQ mice with advanced stage MM. Our study provides a strong rationale to develop MEK inhibition-based therapies for treating advanced/relapsed MM.

2020-07-02 | GSE153626 | GEO

Transcriptomic profiling of normal plasma cells and MM models using bulk RNA-Seq

Project description:Transcriptomic profiling of normal plasma cells and MM models using bulk RNA-Seq

| PRJNA643511 | ENA

MM in murine models: WES

Project description:MM in murine models: WES

| PRJEB18119 | ENA

Emticicia sp. MM strain:MM

Project description:Emticicia sp. MM strain:MM Genome sequencing and assembly

| PRJNA316534 | ENA

Cellulosimicrobium sp. MM strain:MM

Project description:Cellulosimicrobium sp. MM strain:MM Genome sequencing and assembly

| PRJNA255748 | ENA

Sonic Hedgehog subgroup medulloblastomas

Project description:Sonic Hedgehog subgroup medulloblastomas

| PRJNA384622 | ENA

β-thalassemia plasma EVs proteomics

Project description:Here, we performed plasma extracellular vesicles (EVs) proteomics on 20 β-thalassemia major (TM) patients, 20 intermedia (TI) patients, and 20 healthy controls to explore the subgroup characteristics and the potential biomarkers. The proteome of paired plasma was analyzed in parallel to compare the biomarker potential of both specimens. We first described the pathophysiological characteristics of different subtypes. More significant immunity abnormalities and lipid metabolism was separately observed in patients with TI and TM, which was consistent with the results of paired plasma proteomics. A diagnostic model consisting of six proteins with subtyping potential was proposed. Of note, superior performance of plasma EVs on patient subgroup differentiating was shown than plasma, demonstrating the potential of secreted EVs for diagnosis of β-thalassemia patients.

2022-06-15 | PXD034548 |

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data